The Influence of Caerulomycin A on the Intestinal Microbiota in SD Rats
1
Key Laboratory of Marine Drugs, Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
2
Open Studio for Druggability Research of Marine Natural Products, Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266003, China
*
Author to whom correspondence should be addressed.
Mar. Drugs 2020, 18(5), 277; https://doi.org/10.3390/md18050277
Received: 14 April 2020
/
Revised: 20 May 2020
/
Accepted: 20 May 2020
/
Published: 22 May 2020
(This article belongs to the Special Issue Development and Application of Marine-Sourced Anti-cancer and Cancer Pain Control Agents)
Caerulomycin A (CRM A) is the first example of natural caerulomycins with a 2,2′-bipyridyl ring core and 6-aldoxime functional group from Streptomyces caeruleus and recently from marine-derived Actinoalloteichus cyanogriseus WH1-2216-6. Our previous study revealed that CRM A showed anti-tumor activity against human colorectal cancer (CRC) both in vitro and in vivo. Because some intestinal flora can affect the occurrence and development of CRC, the influence of CRM A on the intestinal flora is worthy of study in Sprague–Dawley (SD) rats. The high throughput sequencing of the V3-V4 hypervariable region in bacterial 16S rDNA gene results showed that the CRM A affected the diversity of intestinal flora of the SD rats treated with CRM A for 2, 3 and 4 weeks. Further analysis indicated that the abundance of genera Prevotella_1, Prevotellaceae_UCG-001, and Lactobacillus were increased while the that of genera Alloprevotella and Ruminiclostridium_1 were decreased. For the CRC related intestinal flora, the abundance of genera Bacteroides, Fusobacterium, Enterococcus, Escherichia-Shigella, Klebsiella, Streptococcus, Ruminococcus_2, and Peptococcus of SD rats treated with CRM A were decreased, while that of abundance of genera Bifidobacterium, Lactobacillus, Faecalibacterium, Blautia, Oscillibacter, and Clostridium were increased. The results indicated that CRM A could influence the intestinal flora by inhibiting some species of harmful flora and improving the beneficial bacteria in intestinal flora in the SD rats. The results may provide a new idea for revealing the mechanism of the anti-CRC activity of CRM A.
View Full-Text
Keywords:
intestinal flora; 16S rDNA gene high-throughput sequencing; caerulomycin A; colorectal cancer
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 175 KiB)
MDPI and ACS Style
Zhang, H.; Lan, M.; Cui, G.; Zhu, W. The Influence of Caerulomycin A on the Intestinal Microbiota in SD Rats. Mar. Drugs 2020, 18, 277. https://doi.org/10.3390/md18050277
AMA Style
Zhang H, Lan M, Cui G, Zhu W. The Influence of Caerulomycin A on the Intestinal Microbiota in SD Rats. Marine Drugs. 2020; 18(5):277. https://doi.org/10.3390/md18050277
Chicago/Turabian StyleZhang, Hongwei, Mengmeng Lan, Guodong Cui, and Weiming Zhu. 2020. "The Influence of Caerulomycin A on the Intestinal Microbiota in SD Rats" Marine Drugs 18, no. 5: 277. https://doi.org/10.3390/md18050277
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
